{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:36:26Z","timestamp":1790393786615,"version":"4.1.0"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmpt-2023-0050_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Tamsulosin is a first-line drug for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Despite its high ratings for efficacy and safety, these parameters may vary due to\u00a0genetic polymorphisms of CYP2D6 enzyme, which is involved in the metabolism of the drug. This variability may have great impact on the therapy of LUTS associated with BPH and may require an individualized approach to drug selection. The aim of the study was to assess the impact of genetic polymorphisms in CYP2D6 on the efficacy and safety of tamsulosin therapy in patients with LUTS associated with BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2023-0050_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 106 patients with LUTS\/BPH (N40 according to ICD-10). All patients received monotherapy with tamsulosin 0.4\u202fmg\/day for at least 8\u00a0weeks. Depending on the severity of symptoms, all patients were divided into 2 groups based on the IPSS score: the first group of patients had moderate symptoms (n=57), and the second group of patients had severe symptoms (n=49). The results of treatment were assessed using the IPSS questionnaire with determination of quality of life (QoL), transrectal ultrasound of the prostate with determination of prostate volume and\u00a0postvoid residual urine volume, and uroflowmetry. The carriage of allelic variants of CYP2D6 (*3, *4, *9, *10, and *41) were determined by polymerase chain reaction in all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2023-0050_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In patients with moderate symptoms who was classified as \u00abintermediate\u00bb metabolizers by CYP2D6, a statistically significant greater reduction in symptoms according to the overall IPSS scale at 8\u00a0weeks (p=0.046) and the obstructive symptom subscale starting from 4\u00a0weeks of treatment (p&lt;0.05) was shown. Allelic variants of the CYP2D6 gene did not affect the frequency of adverse reactions to tamsulosin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2023-0050_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of the study show that in patients with moderate LUTS associated with BPH who are \u00abintermediate\u00bb metabolizers by CYP2D6, there is a better therapeutic effect of tamsulosin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2023-0050","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:10:10Z","timestamp":1693559410000},"page":"323-330","source":"Crossref","is-referenced-by-count":4,"title":["Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-1534","authenticated-orcid":false,"given":"Skokhrukh P.","family":"Abdullaev","sequence":"first","affiliation":[{"name":"Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim N.","family":"Shatokhin","sequence":"additional","affiliation":[{"name":"Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"},{"name":"Central Clinical Hospital of \u201cRussian Railways Medicine\u201d , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana N.","family":"Tuchkova","sequence":"additional","affiliation":[{"name":"Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherzod P.","family":"Abdullaev","sequence":"additional","affiliation":[{"name":"Central Clinical Hospital of \u201cRussian Railways Medicine\u201d , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg V.","family":"Teodorovich","sequence":"additional","affiliation":[{"name":"Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"},{"name":"Central Clinical Hospital of \u201cRussian Railways Medicine\u201d , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg B.","family":"Loran","sequence":"additional","affiliation":[{"name":"Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Sychev","sequence":"additional","affiliation":[{"name":"Department of endoscopic urology , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"2025121207123408391_j_dmpt-2023-0050_ref_001","doi-asserted-by":"crossref","unstructured":"Lokeshwar, SD, Harper, BT, Webb, E, Jordan, A, Dykes, TA, Neal, DE, et al.. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019;8:529\u201339. https:\/\/doi.org\/10.21037\/tau.2019.10.01.","DOI":"10.21037\/tau.2019.10.01"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_002","doi-asserted-by":"crossref","unstructured":"Parsons, JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010;5:212\u20138. https:\/\/doi.org\/10.1007\/s11884-010-0067-2.","DOI":"10.1007\/s11884-010-0067-2"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_003","unstructured":"Cornu, JN, Gacci, M, Hashim, H, Herrmann, TR, Malde, S, Netsch, C, et al.. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023 Arnhem, The Netherlands: EAU Guidelines Office. ISBN 978-94-92671-19-6."},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_004","doi-asserted-by":"crossref","unstructured":"Michel, MC, Kenny, B, Schwinn, DA. Classification of alpha 1-adrenoceptor subtypes. Naunyn-Schmiedeb Arch Pharmacol 1995;352:1\u201310. https:\/\/doi.org\/10.1007\/bf00169183.","DOI":"10.1007\/BF00169183"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_005","unstructured":"Rasner, PI, Pushkar, DI. Lechenie simptomov nizhnikh mochevykh putei u patsientov s dobrokachestvennoi giperplaziei predstatel\u2019noi zhelezy: sovremennye mezhdunarodnye standarty. Sprav Poliklin Vracha 2015;10:20\u20136."},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_006","unstructured":"Roehrborn, CG. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009;11:S1\u20138."},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_007","doi-asserted-by":"crossref","unstructured":"Kim, KA, Park, IB, Park, JY. Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans. Eur J Clin Pharmacol 2018;74:1281\u20139. https:\/\/doi.org\/10.1007\/s00228-018-2501-x.","DOI":"10.1007\/s00228-018-2501-x"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_008","doi-asserted-by":"crossref","unstructured":"Choi, CI, Bae, JW, Jang, CG, Lee, SY. Tamsulosin exposure is significantly increased by the CYP2D6*10\/*10 genotype. J Clin Pharmacol 2012;52:1934\u20138. https:\/\/doi.org\/10.1177\/0091270011432168.","DOI":"10.1177\/0091270011432168"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_009","doi-asserted-by":"crossref","unstructured":"Villapalos-Garc\u00eda, G, Zubiaur, P, Navares-G\u00f3mez, M, Saiz-Rodriguez, M, Mejia-Abril, G, Martin-Vilchez, S, et al.. Effects of cytochrome P450 and transporter polymorphisms on the bioavailability and safety of dutasteride and tamsulosin. Front Pharmacol 2021;12:718281. https:\/\/doi.org\/10.3389\/fphar.2021.718281.","DOI":"10.3389\/fphar.2021.718281"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_010","doi-asserted-by":"crossref","unstructured":"Taylor, C, Crosby, I, Yip, V, Maguire, P, Pirmohamed, M, Turner, RM. A Review of the important role of CYP2D6 in pharmacogenomics. Genes 2020;11:1295. https:\/\/doi.org\/10.3390\/genes11111295.","DOI":"10.3390\/genes11111295"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_011","doi-asserted-by":"crossref","unstructured":"Gaedigk, A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatr 2013;25:534\u201353. https:\/\/doi.org\/10.3109\/09540261.2013.825581.","DOI":"10.3109\/09540261.2013.825581"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_012","doi-asserted-by":"crossref","unstructured":"Elens, L, van Gelder, T, Hesselink, DA, Haufroid, V, van Schaik, RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013;14:47\u201362. https:\/\/doi.org\/10.2217\/pgs.12.187.","DOI":"10.2217\/pgs.12.187"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_013","doi-asserted-by":"crossref","unstructured":"Caudle, KE, Sangkuhl, K, Whirl-Carrillo, M, Swen, JJ, Haidar, CE, Klein, TE, et al.. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci 2020;13:116\u201324. https:\/\/doi.org\/10.1111\/cts.12692.","DOI":"10.1111\/cts.12692"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_014","doi-asserted-by":"crossref","unstructured":"Pushkar, DY, Rasner, PI, Kharchilava, RR. Lower urinary tract symptoms and benign prostatic hyperplasia. Urologiia 2016;2:4\u201319. https:\/\/doi.org\/10.18565\/urol.2017.3-supplement.4-18.","DOI":"10.18565\/urol.2017.3-supplement.4-18"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_015","doi-asserted-by":"crossref","unstructured":"Brockm\u00f6ller, J, Tzvetkov, MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 2008;64:133\u201357. https:\/\/doi.org\/10.1007\/s00228-007-0424-z.","DOI":"10.1007\/s00228-007-0424-z"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_016","unstructured":"Mini, E, Nobili, S. Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 2009;6:17\u201324."},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_017","doi-asserted-by":"crossref","unstructured":"Samani, NJ, Tomaszewski, M, Schunkert, H. The personal genome-the future of personalised medicine? Lancet 2010;375:1497\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(10)60598-3.","DOI":"10.1016\/S0140-6736(10)60598-3"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_018","doi-asserted-by":"crossref","unstructured":"Collins, FS, Varmus, H. A new initiative on precision medicine. N Engl J\u00a0Med 2015;372:793\u20135. https:\/\/doi.org\/10.1056\/nejmp1500523.","DOI":"10.1056\/NEJMp1500523"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_019","doi-asserted-by":"crossref","unstructured":"Zanger, UM, Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007.","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_020","unstructured":"CYP2D6 CPIC, guidelines. [Internet]. Stanford University & St. Jude Children\u2019s Research Hospital. Available from: https:\/\/cpicpgx.org\/gene\/cyp2d6\/."},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_021","unstructured":"Boehringer Ingelheim GmbH Flomax (tamsulosin hydrochloride). Highlights of prescribing information. 2016. http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Flomax+Caps\/Flomax.pdf [Assessed 22 May 2018]."},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_022","doi-asserted-by":"crossref","unstructured":"Troost, J, Tatami, S, Tsuda, Y, Mattheus, M, Mehlburger, L, Wein, M, et al.. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 2011;72:247\u201356. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03988.x.","DOI":"10.1111\/j.1365-2125.2011.03988.x"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_023","doi-asserted-by":"crossref","unstructured":"Roehrborn, CG, Schwinn, DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171:1029\u201335. https:\/\/doi.org\/10.1097\/01.ju.0000097026.43866.cc.","DOI":"10.1097\/01.ju.0000097026.43866.cc"},{"key":"2025121207123408391_j_dmpt-2023-0050_ref_024","doi-asserted-by":"crossref","unstructured":"Wilt, TJ, Howe, W, MacDonald, R. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2002;89:214\u201325. https:\/\/doi.org\/10.1046\/j.1464-4096.2001.02537.x-i1.","DOI":"10.1046\/j.1464-4096.2001.02537.x-i1"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2023-0050\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2023-0050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:00:13Z","timestamp":1765526413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2023-0050\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2024,1,4]]}},"alternative-id":["10.1515\/dmpt-2023-0050"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2023-0050","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}